Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSRT + IMRT + Temozolomide for Glioblastoma
NCT04547621Phase 2Unknown
- Sponsor
- Huashan Hospital
- Start
- Sep 2020
- Primary completion
- Jan 2023
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by Huashan Hospital. Primary endpoint: Overall Survival at 24 months. Status: unknown.
Beyond the preview
Go deeper on NCT04547621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04547621.